ClinicalTrials.gg
RecruitingNCT06179602A-IMAGIOUpdated Sep 10, 2025

Prospective Cohort Study on Thermal Ablation of Malignant Liver Tumors

An observational study in Liver Cancer, Liver Metastases and Liver Metastasis Colon Cancer, sponsored by Leiden University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Primary conditionCarcinoma, HepatocellularRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's listed conditions name Carcinoma, Hepatocellular, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Leiden University Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Ages
18 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies in Carcinoma, Hepatocellular with a site in Netherlands — 19 open to participants now, 23 under way, 4 of them phase 3. Carcinoma, Hepatocellular · Netherlands.

Planned enrollment
7th of 13
1,500 · median 1,500
Started
2024
with 2 others
Observational
13 of 53
6 open now
Primary completion
2027-12
later than 12 of 22 live
Registered
43rd of 53
by date
Lead sponsor
2 of 53
Leiden University Medical Center

Among the 53 studies in Carcinoma, Hepatocellular with a site in Netherlands, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 43rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

19 of the 53 studies in Carcinoma, Hepatocellular with a site in Netherlands are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Carcinoma, Hepatocellular with a site in Netherlands, or all of them as a file.
02

Study summary

The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.

Read the detailed description

This study is part of the IMAGIO (Imaging and advanced guidance for workflow optimization in interventional oncology) project. This project aims to leverage Interventional Oncology in the clinical setting to improve cancer survival outcomes, through minimally invasive, efficient and affordable care pathways for three disease states; liver cancer, lung cancer and sarcoma. In IMAGIO, top innovators in MedTech and Pharma and expert academic clinical centers will mature the next-generation interventional oncology imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials.

The objective of this study, A-IMAGIO, is to develop a standardized, accessible, low-complex, end-to-end solution for patient selection, treatment planning, needle guidance and treatment evaluation for thermal liver ablation.

One of the objectives is to integrate AI in the clinical workflow as a tool to assist operators in decision making throughout the entire process based on quantitative assessment. AI data analytics will be developed to guide decision making for personalized treatment together with algorithms that allow optimized treatment planning and automated quantitative treatment evaluation. Also, a computational model will be developed with input from radiomics and clinical data to identify patients at risk of recurrence after thermal ablation. The aim of the A-IMAGIO project is to conduct a large European observational cohort study and collect clinical and image data of patients treated with thermal ablation for liver tumors in order to develop and validate these AI algorithms. The database will be built by merging data from retrospective data and previous prospective clinical trials on thermal ablation of liver tumors. Further data will be collected through a prospective, multicenter, observational study. The long-term objective is to establish thermal ablation as the first line therapy for patients with both primary and secondary liver tumors. Therefore, we aim to develop a low-complexity-high-precision, accessible workflow that can be widely implemented in different centers performing thermal ablation.

03

Conditions studied

  • Liver Cancer
  • Liver Metastases
  • Liver Metastasis Colon Cancer
  • Hepatocellular Carcinoma

Browse trials for

04

In context

Carcinoma, Hepatocellular Reclassified

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients diagnosed with one or more primary or secondary liver malignancy who are candidates for thermal liver ablation as discussed in a multidisciplinary tumour board.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or above
  • Candidate for percutaneous thermal liver ablation as discussed in a multidisciplinary tumorboard (MDT)

Exclusion criteria

Exclusion Criteria:

  • Patients lacking capacity to give .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Efficacy as assessed by local recurrence

    Time frame: Throughout the entire four-year study period

  2. Efficacy as assessed by time-to-recurrence

    Time frame: Throughout the entire four-year study period

  3. Efficacy as assessed by disease-free-survival

    Time frame: Throughout the entire four-year study period

  4. Efficacy as assessed by overall survival

    Time frame: Throughout the entire four-year study period

  5. Safety as assessed by complications according to CTCAE v6.0.

    Treatment related adverse events are defined as grade 3-4 adverse events and serious

    Time frame: Throughout the entire four-year study period

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • van der Velden AL, Verhagen CAM, Gholamiankhah F, Rahmani H, van Dam RM, van Duijn-de Vreugd JJ, Simon SR, Hendriks P, van Erp GCM, Knapen RRMM, Volmer L, Overduin K, Braak JPBM, Bale R, Laimer G, Lanocita R, Meijerink MR, Kampfer Y, Denys A, Littler P, Sternberg B, Kobeiter H, Smits MLJ, van Strijen MJL, Pieterman KJ, Broersen A, Dijkstra J, Brecheisen R, Burgmans MC, van der Leij C. Prospective Registry Study on Thermal Liver Ablation of Primary and Secondary Liver Tumours Named the A-IMAGIO Study. Cardiovasc Intervent Radiol. 2025 Aug;48(8):1193-1199. doi: 10.1007/s00270-025-04093-9. Epub 2025 Jun 23. PubMed 40550852 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 47 months is below that.

Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 22, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Dec 15, 2027
CompletionEst.
Jan 1, 2028
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06179602
Collaborators
Philips Healthcare, European Commission
Responsible party
Mark C Burgmans, MD PhD (Dr. M. C. Burgmans, MD PhD, Leiden University Medical Center) — Principal investigator
First posted
Dec 22, 2023
Start date
Jan 1, 2024
Primary completion
Dec 15, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Sep 10, 2025

Study contacts

Coosje A. M. Verhagen, Drs.
Contact
c.a.m.verhagen@lumc.nl
+31-71-5264376
Ariadne L. Velden, van der, Drs.
Contact
lisa.van.der.velden@mumc.nl
+31(0)43-3876910
Mark C. Burgmans, MD PhD
principal investigator · Leiden univeristy medical centre
Christiaan van der Leij, MD PhD
principal investigator · Maastricht University Medical Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion